Layered double hydroxides as supports for intercalation and sustained release of antihypertensive drugs

Xia, Shengjie; Zhang, Ni; Xu, Qian; Hu, Baoxiang; Hu, Jun

doi:10.1016/j.jssc.2008.06.009

Cited by 94 publications

(63 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported in the literature, the (003) reflection for the precursor Zn/Al-NO 3 LDH appears at 9.98°, indicating a d spacing of 8.90 Å. 13 The shifting of this reflection toward low 2θ (2θ = 8.06°, corresponding to a d spacing of 10.9 Å) for the nanocomposite indicates intercalation of levodopa into the interlayer galleries of the LDH. The characteristic reflections of levodopa, shown in Figure 1B, were absent from the X-ray diffraction pattern of the nanocomposite, suggesting that levodopa was intercalated into the interlayer galleries rather than absorbed at the surface.…”

Section: Results and Discussion Powder X-ray Diffractionmentioning

confidence: 54%

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Kura¹,

Ali²,

Hussein³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct coprecipitation method. The resulting nanocomposite was composed of the organic moiety, levodopa, sandwiched between Zn/Al-LDH inorganic interlayers. The basal spacing of the resulting nanocomposite was 10.9 Å. The estimated loading of levodopa in the nanocomposite was approximately 16% (w/w). A Fourier transform infrared study showed that the absorption bands of the nanocomposite were characteristic of both levodopa and Zn/Al-LDH, which further confirmed intercalation, and that the intercalated organic moiety in the nanocomposite was more thermally stable than free levodopa. The resulting nanocomposite showed sustained-release properties, so can be used in a controlled-release formulation. Cytotoxicity analysis using an MTT assay also showed increased cell viability of 3T3 cells exposed to the newly synthesized nanocomposite compared with those exposed to pure levodopa after 72 hours of exposure.

show abstract

Section: Results and Discussion Powder X-ray Diffractionmentioning

confidence: 54%

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Kura¹,

Ali²,

Hussein³

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…It is clear that an ideal level of pH in the blood is about 7.4, and even changing this level slightly may have fatal consequences. Therefore, release of gallic acid from nanoparticles was determined using a 0.0001 M aqueous solution of Na 2 CO 3 32 and Na 3 PO 4 buffered solutions of pH 4.8 [33][34][35][36][37][38][39] and 7.4 37,38,40,41 at 37°C. The gallic acid released was measured at preset times using ultraviolet-visible spectrophotometry at 264 nm.…”

Section: Characterizationmentioning

confidence: 99%

Preparation of Fe3O4 magnetic nanoparticles coated with gallic acid for drug delivery

Dorniani¹,

Hussein²,

Kura³

et al. 2012

IJN

181

View full text Add to dashboard Cite

Background and methods: Magnetic iron oxide nanoparticles were prepared using a sonochemical method under atmospheric conditions at a Fe 2+ to Fe 3+ molar ratio of 1:2. The iron oxide nanoparticles were subsequently coated with chitosan and gallic acid to produce a core-shell structure.Results: X-ray diffraction demonstrated that the magnetic nanoparticles were pure Fe 3 O 4 with a cubic inverse spinel structure. Transmission electron microscopy showed that the Fe 3 O 4 nanoparticles were of spherical shape with a mean diameter of 11 nm, compared with 13 nm for the iron oxide-chitosan-gallic acid (FCG) nanocarriers. Conclusion:The magnetic nanocarrier enhanced the thermal stability of the drug, gallic acid. Release of the active drug from the FCG nanocarrier was found to occur in a controlled manner. The gallic acid and FCG nanoparticles were not toxic in a normal human fibroblast (3T3) line, and anticancer activity was higher in HT29 than MCF7 cell lines.

show abstract

“…The release of cetirizine from CETN into the medium of phosphate buffer solution at pH 7.4 and pH 4.8 [22][23][24] was achieved by adding about 85 mg of CETN into 250 mL buffer solutions. The accumulated amount of cetirizine released into the solutions was measured at different times using a UV-visible spectrophotometer at 231 nm.…”

Section: Loading and Release Amounts Of Cetirizine In Cetnmentioning

confidence: 99%

Controlled-release formulation of antihistamine based on cetirizine zinc-layered hydroxide nanocomposites and its effect on histamine release from basophilic leukemia (RBL-2H3) cells

Hasan¹,

Ali²,

Al‐Qubaisi³

et al. 2012

IJN

View full text Add to dashboard Cite

Abstract:A controlled-release formulation of an antihistamine, cetirizine, was synthesized using zinc-layered hydroxide as the host and cetirizine as the guest. The resulting well-ordered nanolayered structure, a cetirizine nanocomposite "CETN," had a basal spacing of 33.9 Å, averaged from six harmonics observed from X-ray diffraction. The guest, cetirizine, was arranged in a horizontal bilayer between the zinc-layered hydroxide (ZLH) inorganic interlayers. Fourier transform infrared spectroscopy studies indicated that the intercalation takes place without major change in the structure of the guest and that the thermal stability of the guest in the nanocomposites is markedly enhanced. The loading of the guest in the nanocomposites was estimated to be about 49.4% (w/w). The release study showed that about 96% of the guest could be released in 80 hours by phosphate buffer solution at pH 7.4 compared with about 97% in 73 hours at pH 4.8. It was found that release was governed by pseudo-second order kinetics. Release of histamine from rat basophilic leukemia cells was found to be more sensitive to the intercalated cetirizine in the CETN compared with its free counterpart, with inhibition of 56% and 29%, respectively, at 62.5 ng/mL. The cytotoxicity assay toward Chang liver cells line show the IC 50 for CETN and ZLH are 617 and 670 μg/mL, respectively.

show abstract

Layered double hydroxides as supports for intercalation and sustained release of antihypertensive drugs

Cited by 94 publications

References 42 publications

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Preparation of Fe3O4 magnetic nanoparticles coated with gallic acid for drug delivery

Controlled-release formulation of antihistamine based on cetirizine zinc-layered hydroxide nanocomposites and its effect on histamine release from basophilic leukemia (RBL-2H3) cells

Contact Info

Product

Resources

About